Evidence map›Paper›PMID 25927667›Full record

Trial reportWorld journal of surgical oncology2015

Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review.

Lawrence A Shirley, Megan McNally, Ravi Chokshi, Natalie Jones, Patrick Tassone, Gregory Guy, Hooman Khabiri, Carl Schmidt, Manisha Shah, Mark Bloomston

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Lawrence A ShirleyDivision of Surgical Oncology, The Ohio State University Wexner Medical Center, N924 Doan Hall, 410 W. 10th Ave, Columbus, OH, 43210, USA. lawrence.shirley@osumc.edu.
Megan McNallyDepartment of Surgery, Saint Luke's Health System and University of Missouri-Kansas City, 100 NE St. Lukes Blvd, Lee's Summit, MO 64086, USA. memcnally81@gmail.com.
Ravi ChokshiDivision of Surgical Oncology, Rutgers University-New Jersey Medical School, 205 South Orange Avenue, G-1222, Newark, NJ 07103, USA. chokshrj@njms.rutgers.edu.
Natalie JonesDepartment of Surgery, Riverside Methodist Hospital, 1654 Upham Dr., Columbus, OH, 43210, USA. jonesnatalieb@gmail.com.
Patrick TassoneDepartment of Otolaryngology, Thomas Jefferson University Hospital, 925 Chestnut Street, 6th Floor, Philadelphia, PA, 19107, USA. p.t.tassone@gmail.com.
Gregory GuyDepartment of Radiology, The Ohio State University Wexner Medical Center, Room 460, 395 W. 12th Ave, Columbus, OH, 43210, USA. Gregory.guy@osumc.edu.
Hooman KhabiriDepartment of Radiology, The Ohio State University Wexner Medical Center, Room 460, 395 W. 12th Ave, Columbus, OH, 43210, USA. hooman.khabiri@osumc.edu.
Carl SchmidtDivision of Surgical Oncology, The Ohio State University Wexner Medical Center, N924 Doan Hall, 410 W. 10th Ave, Columbus, OH, 43210, USA. carl.schmidt@osumc.edu.
Manisha ShahDivision of Medical Oncology, The Ohio State University Wexner Medical Center, 4th Floor Starling Loving Hall, 320 W. 10th Ave, Columbus, OH, 43210, USA. manisha.shah@osumc.edu.
Mark BloomstonDivision of Surgical Oncology, The Ohio State University Wexner Medical Center, N924 Doan Hall, 410 W. 10th Ave, Columbus, OH, 43210, USA. mark.bloomston@osumc.edu.
The Ohio State University Wexner Medical Center · USRiverside Methodist Hospital · USRutgers, The State University of New Jersey · USSaint Luke's Health System · USThomas Jefferson University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCaudate lobe liver metastases occur commonly in patients with neuroendocrine tumors. It is unknown, however, how these lesions respond to regional therapy and how their presence impacts outcomes. We reviewed our experience treating these lesions using transarterial chemoembolization (TACE).

methodsWe reviewed radiographic response to TACE in 86 patients with metastatic neuroendocrine tumors to the liver. We determined the impact of caudate lesions on outcomes in comparison to the cohort of patients without caudate lesions, as well as response of caudate lesions to TACE versus lesions elsewhere in the liver.

resultsCaudate lesions were identified in 45 (52%) patients. All patients had disease in other liver segments. Only seven caudate lesions (12.3%) had a radiographic response to TACE, whereas 82% of lesions elsewhere in the liver demonstrated a response. The presence or absence of a caudate lesion did not impact the overall radiographic (82.2% vs. 82.9%), symptomatic (64.4% vs. 56.1%), or biochemical (97.6% vs. 88.9%) response to TACE (P > 0.1 for all). However, median overall survival was reduced in those presenting with caudate lesions (87.1 vs. 45.6 months, P = 0.031).

conclusionsMetastatic neuroendocrine tumors to the caudate lobe respond poorly to TACE. Symptomatic or threatening caudate lobe lesions should be considered for palliative resection in spite of additional inoperable liver metastases.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemoembolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingNeuroendocrine TumorsPrognosisSurvival Rate

Identifiers

PMID25927667
PMCPMC4423113
OpenAlexW2132270685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.